Clinical stage drug company engineering drug combinations to accelerate neuroplasticity (brain's capacity to rebuild, rewire, and repair). Target patients are those suffering brain injuries, deterioration, or disease. Enhancing neuroplasticity is instrumental to combat or heal a range of neurologic conditions, e.g., aging, dementia, depression, movement disorders, stroke deficits, psychiatric illness, cognition deficits. These ailments represent large financial and emotional burdens to families, communities, and nations and multiple multi-billion dollar markets.